Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07489287 · ClinicalTrials.gov registry record · Phase 1
GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT07489287 is a Phase 1 study that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 18 participants.
The verdict
NCT07489287, a Phase 1 study, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This phase 1 study evaluates the safety, efficacy, and biological activity of GB-5267 in patients with platinum-resistant ovarian cancer.
Interventions
- BIOLOGICAL GB-5267 - IV only
- BIOLOGICAL GB-5267 -Combined IV and IP Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2030-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07489287
The ClinicalTrials.gov registry entry for NCT07489287 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GB-5267 - IV only is the first listed.
NCT07489287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07489287 about?
NCT07489287 is a clinical study titled "GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer". This phase 1 study evaluates the safety, efficacy, and biological activity of GB-5267 in patients with platinum-resistant ovarian cancer.
What is the current status of trial NCT07489287?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-07-15. Estimated completion is 2030-01-15.
What interventions are being tested in trial NCT07489287?
The interventions under investigation include: GB-5267 - IV only (BIOLOGICAL), GB-5267 -Combined IV and IP Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT07489287?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.